Replies to post #8 on Allos Therapeutics Inc. (ALTH)

[coinstarz]

I speculate Tim resigning was to sell his TRCA options (approx. $1 M). And his credentials will land another better deal in other biotech company. I also think Warburg likes him because he has wall street experience and knows how to play with them. Tim has no job title yet but BOD since he joined ALTH last Nov. 2005. He will be soon assigned to CFO or VP. I am not sure he will be CEO since he has no medical/biological background.

ALTH is an investment fund controlled company. That is a good thing for shareholders. The tradable float is less than 7 M shares. Any kind of good news will double or triple the pps.

Well, Tim's departure is not good to TRCA (TRCA cannot find an outsider to fill the space). he knows Increlex's future is limited.

http://finance.yahoo.com/q/it?s=TRCA

6-Jul-05 LYNCH, TIMOTHY P
107,009 Direct Planned Sale $963,000